Mydecine Innovations Group Inc. Signs Definitive Agreement For Acquisition Of NeuroPharm Inc.

Mydecine Innovations Group Inc. (Mydecine), announced further to its press release on June 10, 2020, it has entered into a definitive share exchange agreement of 100% of NeuroPharm Inc. (NeuroPharm), a Canadian-based developer of natural psychedelic-based treatments for mental health disorders in the Canadian and United States veteran communities. Financial terms have not been disclosed.

NeuroPharm, in collaboration with its strategic partners, is deploying evidence-based medicine in the establishment of psychedelic-based therapies addressing the unmet needs of high-risk constituents. NeuroPharm is focused on developing unique and proprietary technologies to treat various mental health conditions frequently . . .